283 related articles for article (PubMed ID: 18447599)
1. Axitinib for renal cell carcinoma.
Sonpavde G; Hutson TE; Rini BI
Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
[TBL] [Abstract][Full Text] [Related]
2. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
4. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
5. Axitinib (Inlyta) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
[No Abstract] [Full Text] [Related]
6. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
7. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
8. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
[TBL] [Abstract][Full Text] [Related]
9. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
10. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
11. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
[TBL] [Abstract][Full Text] [Related]
12. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
13. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
15. Axitinib: a review in advanced renal cell carcinoma.
Keating GM
Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
17. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
18. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
Qin S; Zhang S
Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
[No Abstract] [Full Text] [Related]
19. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
Yang LP; McKeage K
Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib.
Trask PC; Bushmakin AG; Cappelleri JC; Bycott P; Liau K; Kim S
Acta Oncol; 2008; 47(5):843-51. PubMed ID: 18568482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
